Justin Stebbing is a world-renowned cancer specialist, widely regarded as one of the most talented people in his field. Justin is an NIHR Research Professor of Cancer Medicine and Oncology at Imperial College London specializing in immunotherapy for breast, gastrointestinal, and lung cancers. In addition to his global groundbreaking contributions to cancer research, he has extensive work on biosimilars and cheaper versions of expensive biologic drugs designed to democratize access to these around the world in 2020 at the start of the Covid pandemic. Justin has published over 550 peer-reviewed papers in journals such as The Lancet, New England Journal, Blood, the Journal of Clinical Oncology, Annals of Internal Medicine, as well as presenting data at international conferences.
2010 - 2012
2001 - 2003
AWARDS AND RECOGNITION
Elected Member, The American Society for Clinical Investigation
Fellow, Royal College of Physicians
Fellow, Royal College of Pathologists
In cancer, one of his most cited papers includes the discovery of the role of the oncogene LMTK3 across malignancies.
He is also cited for the network of microRNAs induced by the estrogen receptor, and extensive work on HIV and AIDS cancers.
His laboratory work is concentrated on druggable target discovery, biomarkers of response and the role of immunotherapy.
Justin has appeared as a guest on Real Vision.
AFFILIATIONS AND INVOLVEMENT
Scientific Advisor, BenevolentAI
Advisory Board, Heat Biologics
Senior Advisor, Greenmantle
Editor in Chief - Oncogene, Springer Nature
Board Member, BB Healthcare Trust
Professor of Cancer Medicine and Oncology, Action Against Cancer
World Vaccine Congress